

# Exploring the Therapeutic Potential of Cannabinoids in Neurological Disorders

David Wheeler

Division of Medicine, University College London, UK

**Article history:** Received: 15 June 2019, Accepted: 20 July 2019, Published online: 25 July 2019.

## ABSTRACT

Neurological disorders encompass a broad spectrum of conditions ranging from epilepsy to Alzheimer's disease, each presenting unique challenges in treatment and management. Over recent years, there has been growing interest in the therapeutic potential of cannabinoids, compounds derived from the *Cannabis sativa* plant, in addressing these disorders. This abstract delves into the current state of research surrounding the use of cannabinoids in neurological disorders, focusing on their mechanisms of action, efficacy, and safety profiles. Cannabinoids interact with the endocannabinoid system, a complex network of receptors and neurotransmitters involved in regulating various physiological processes, including neuronal function and inflammation. Through their modulation of this system, cannabinoids exert diverse effects on neurological function, offering promise in alleviating symptoms associated with neurological disorders. Epilepsy, for instance, has garnered considerable attention due to the success of cannabidiol (CBD), a non-psychoactive cannabinoid, in reducing seizure frequency and severity in certain forms of the condition. Additionally, cannabinoids have shown potential in managing symptoms of neurodegenerative diseases like Parkinson's and Alzheimer's, with evidence suggesting neuroprotective properties and the ability to mitigate neuroinflammation and oxidative stress. However, despite promising preclinical and clinical findings, challenges remain in fully harnessing the therapeutic potential of cannabinoids. Regulatory hurdles, variability in cannabinoid formulations and dosages, and limited understanding of long-term effects pose significant barriers to widespread adoption. Furthermore, the psychoactive properties of some cannabinoids, notably delta-9-tetrahydrocannabinol (THC), necessitate careful consideration of potential cognitive and psychomotor side effects.

**Keywords:** Cannabinoids, Neurological Disorders, Therapeutic Potential, Endocannabinoid System, Epilepsy.

## INTRODUCTION

Neurological disorders pose significant challenges to healthcare systems worldwide, affecting millions of individuals and their families. From epilepsy and multiple sclerosis to Alzheimer's disease and Parkinson's disease, these disorders encompass a broad spectrum of conditions characterized by dysfunction in the nervous system. Despite advancements in medical science, many neurological disorders lack effective treatments, leaving patients with limited therapeutic options and often debilitating symptoms.

In recent years, there has been growing interest in exploring alternative therapeutic approaches, particularly those involving cannabinoids derived from the *Cannabis sativa* plant. Cannabinoids, the active compounds in cannabis, have garnered attention for their potential to modulate various physiological processes, including those relevant to neurological function. The endocannabinoid system, comprising cannabinoid receptors, endogenous ligands, and enzymes, plays a crucial role in regulating neuronal signaling, synaptic plasticity, and inflammation, making it an attractive target for therapeutic intervention in neurological disorders.

This introduction sets the stage for delving into the current state of research on cannabinoids and their therapeutic potential in neurological disorders. By examining the mechanisms of action, preclinical and clinical evidence, as well as the challenges and opportunities associated with cannabinoid-based therapies, this review aims to provide insights into the promise and limitations of harnessing cannabinoids for the treatment of neurological conditions. Ultimately, advancing our understanding of cannabinoids' role in neurological health may lead to the development of novel and more effective therapeutic strategies for individuals living with these challenging disorders.

## LITERATURE REVIEW

The therapeutic potential of cannabinoids in neurological disorders has attracted considerable attention in both preclinical and clinical research settings. Studies investigating the efficacy and safety of cannabinoids have provided valuable insights into their mechanisms of action and potential applications in various neurological conditions.

Epilepsy stands out as one of the most extensively studied neurological disorders in the context of cannabinoid therapy. Preclinical research has demonstrated the anticonvulsant effects of cannabinoids, particularly cannabidiol (CBD), in animal models of epilepsy. Clinical trials have further corroborated these findings, showing promising results in reducing seizure frequency and severity, particularly in patients with refractory epilepsy syndromes such as Dravet syndrome and Lennox-Gastaut syndrome. Beyond epilepsy, cannabinoids have shown potential in managing symptoms associated with neurodegenerative disorders. Parkinson's disease, characterized by dopaminergic neuronal loss and motor dysfunction, has been a focus of investigation. Preclinical studies suggest that cannabinoids may exert neuroprotective effects and alleviate motor symptoms by modulating dopamine neurotransmission and reducing neuroinflammation. Clinical trials exploring the use of cannabinoids in Parkinson's disease are ongoing, aiming to validate these preclinical findings and determine their clinical relevance.

Similarly, Alzheimer's disease, characterized by progressive cognitive decline and neuroinflammation, has been the subject of cannabinoid research. Preclinical studies have demonstrated the neuroprotective properties of cannabinoids, including the ability to reduce amyloid-beta accumulation, enhance neurogenesis, and attenuate neuroinflammation. Clinical studies investigating the effects of cannabinoids on cognitive function and disease progression in Alzheimer's patients are underway, with preliminary findings suggesting potential benefits in improving cognitive outcomes and attenuating neuroinflammation.

Despite the promising findings from preclinical studies and early-phase clinical trials, several challenges remain in the development and implementation of cannabinoid-based therapies for neurological disorders. These include variability in cannabinoid formulations and dosages, limited understanding of the long-term effects of cannabinoids, regulatory hurdles, and concerns regarding psychoactive effects, particularly with delta-9-tetrahydrocannabinol (THC).

In conclusion, while research into the therapeutic potential of cannabinoids in neurological disorders is advancing rapidly, further studies are warranted to elucidate optimal treatment regimens, address safety concerns, and navigate regulatory frameworks. Collaborative efforts between researchers, clinicians,

## **THEORETICAL FRAMEWORK**

The theoretical framework guiding research into the therapeutic potential of cannabinoids in neurological disorders draws upon several key concepts from neuroscience, pharmacology, and clinical medicine.

**Endocannabinoid System (ECS):** Central to the theoretical framework is the ECS, a complex network of cannabinoid receptors (CB1 and CB2), endogenous ligands (such as anandamide and 2-arachidonoylglycerol), and enzymes involved in the synthesis and degradation of endocannabinoids. Understanding the ECS provides insights into how cannabinoids exert their effects on neurological function, including modulation of neurotransmission, synaptic plasticity, and neuroinflammation.

**Neurotransmission and Synaptic Plasticity:** Cannabinoids influence neurotransmitter release and synaptic plasticity through their interactions with the ECS. This includes modulation of gamma-aminobutyric acid (GABA) and glutamate neurotransmission, which are implicated in the pathophysiology of neurological disorders such as epilepsy and neurodegenerative diseases.

**Neuroinflammation and Oxidative Stress:** Neuroinflammation and oxidative stress are common features of many neurological disorders, contributing to neuronal dysfunction and disease progression. Cannabinoids have been shown to exert anti-inflammatory and antioxidant effects, potentially mitigating neuroinflammatory processes and protecting against neuronal damage.

**Neuroprotection and Neurogenesis:** Cannabinoids have been implicated in promoting neuroprotection and neurogenesis, processes essential for maintaining neuronal health and repair. This includes the modulation of neuronal survival pathways, enhancement of neurotrophic factor expression, and stimulation of neural stem cell proliferation and differentiation.

**Clinical Pharmacology and Therapeutics:** Theoretical considerations extend to clinical pharmacology and therapeutics, encompassing pharmacokinetics (absorption, distribution, metabolism, and excretion) and pharmacodynamics (drug-receptor interactions, dose-response relationships) of cannabinoids in the context of neurological disorders. Understanding these principles is crucial for optimizing cannabinoid-based therapies and ensuring their safety and efficacy in clinical practice.

**Biopsychosocial Model of Disease:** Additionally, the theoretical framework may incorporate a biopsychosocial model of disease, recognizing the multifactorial nature of neurological disorders and the importance of addressing biological,

psychological, and social factors in diagnosis, treatment, and management. This holistic approach informs research into cannabinoids as potential therapeutic agents, considering not only their biological effects but also their impact on patient outcomes and quality of life.

By integrating these theoretical concepts, researchers can elucidate the mechanisms underlying the therapeutic effects of cannabinoids in neurological disorders, inform the development of novel treatment strategies, and guide clinical decision-making to improve patient care and outcomes.

## **RECENT METHODS**

**Cellular and Molecular Techniques:** Recent advancements in cellular and molecular biology have enabled researchers to elucidate the mechanisms of action underlying cannabinoid effects on neuronal function. Techniques such as patch-clamp electrophysiology, calcium imaging, and molecular biology tools allow for the study of cannabinoid receptor signaling pathways, neurotransmitter release modulation, and gene expression changes in response to cannabinoid exposure.

**Animal Models of Neurological Disorders:** Preclinical studies rely on animal models to investigate the efficacy and safety of cannabinoid-based therapies in neurological disorders. Recent developments include the generation of transgenic animal models that mimic specific aspects of human neurological conditions, allowing researchers to more accurately assess the therapeutic potential of cannabinoids in relevant disease contexts.

**Neuroimaging Techniques:** Neuroimaging techniques, such as functional magnetic resonance imaging (fMRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT), provide valuable insights into the effects of cannabinoids on brain function and structure in both preclinical and clinical settings. These techniques enable researchers to visualize changes in neural activity, neurotransmitter levels, and brain morphology following cannabinoid administration, informing our understanding of their therapeutic mechanisms and effects on neurological disorders.

**Clinical Trials and Observational Studies:** Recent clinical trials and observational studies have investigated the safety, efficacy, and tolerability of cannabinoid-based therapies in patients with neurological disorders. These studies employ rigorous methodology, including randomized controlled trials (RCTs), double-blind placebo-controlled trials, and longitudinal cohort studies, to evaluate the effects of cannabinoids on disease progression, symptom management, and quality of life outcomes in patient populations.

**Pharmacogenomics and Personalized Medicine:** Advancements in pharmacogenomics have led to increased interest in personalized medicine approaches to cannabinoid therapy. By studying genetic variations in cannabinoid receptor genes, drug metabolism enzymes, and other relevant targets, researchers aim to identify biomarkers that predict individual responses to cannabinoid treatment and optimize therapeutic outcomes for patients with neurological disorders.

**Bioinformatics and Data Analysis:** With the growing volume of data generated from cannabinoid research, bioinformatics and data analysis techniques play a crucial role in extracting meaningful insights from large datasets. Bioinformatic tools facilitate the integration of multi-omics data, including genomics, transcriptomics, proteomics, and metabolomics, to identify molecular pathways and biological networks influenced by cannabinoids in neurological disorders.

## **SIGNIFICANCE OF THE TOPIC**

The significance of exploring the therapeutic potential of cannabinoids in neurological disorders is multifaceted and far-reaching, impacting individuals, healthcare systems, and society as a whole:

**Clinical Need:** Neurological disorders such as epilepsy, Parkinson's disease, Alzheimer's disease, and multiple sclerosis pose significant challenges to patients and healthcare providers due to their often debilitating symptoms and limited treatment options. There is a pressing clinical need for novel, effective therapies to alleviate symptoms, slow disease progression, and improve quality of life for individuals living with these conditions.

**Public Health Impact:** Neurological disorders contribute to a substantial burden of disease globally, affecting millions of people and their families. Addressing the unmet medical needs associated with these conditions has important public health implications, including reducing healthcare costs, improving productivity, and enhancing overall well-being.

**Potential Therapeutic Innovation:** Cannabinoids represent a promising avenue for therapeutic innovation in neurological disorders. Their diverse pharmacological effects, including analgesic, anti-inflammatory, neuroprotective,

and anticonvulsant properties, offer unique opportunities for targeting multiple disease mechanisms and addressing the complex nature of neurological disorders.

**Alternative Treatment Options:** For individuals who have not responded to conventional treatments or experience intolerable side effects, cannabinoid-based therapies may offer alternative treatment options. By diversifying the therapeutic armamentarium, cannabinoids have the potential to provide relief for patients who have exhausted other avenues of treatment.

**Scientific Advancement:** Research into cannabinoids and the endocannabinoid system has broader implications for our understanding of neuroscience and pharmacology. Elucidating the mechanisms of action underlying cannabinoid effects on neuronal function and disease pathogenesis contributes to our knowledge of brain physiology and may uncover novel targets for drug development beyond cannabinoids themselves.

**Policy and Regulatory Considerations:** As attitudes toward cannabis evolve and regulatory frameworks adapt, exploring the therapeutic potential of cannabinoids in neurological disorders raises important policy and regulatory considerations. Balancing patient access to cannabinoid-based therapies with concerns regarding safety, efficacy, and misuse requires evidence-based approaches informed by rigorous scientific research.

In summary, the significance of investigating cannabinoids in neurological disorders lies in its potential to address unmet clinical needs, improve public health outcomes, drive therapeutic innovation, advance scientific knowledge, and inform policy and regulatory decisions. By exploring this topic, researchers can contribute to improving the lives of individuals affected by neurological disorders and shaping the future of healthcare.

## **LIMITATIONS & DRAWBACKS**

While research into the therapeutic potential of cannabinoids in neurological disorders holds promise, it is important to acknowledge several limitations and drawbacks associated with this area of investigation:

**Limited Clinical Evidence:** Despite promising preclinical data, clinical evidence supporting the efficacy of cannabinoids in neurological disorders remains relatively limited. Many studies suffer from small sample sizes, short follow-up periods, and methodological limitations, making it challenging to draw definitive conclusions about the effectiveness of cannabinoid-based therapies.

**Heterogeneity of Cannabinoid Formulations:** The variability in cannabinoid formulations, including differences in cannabinoid ratios, purity, and delivery methods, poses a significant challenge to standardization and reproducibility in research and clinical practice. This heterogeneity makes it difficult to compare study results and determine optimal treatment regimens for specific neurological conditions.

**Safety Concerns:** While cannabinoids are generally well-tolerated, they are not without risks. Adverse effects such as sedation, cognitive impairment, psychomotor dysfunction, and psychiatric symptoms (e.g., anxiety, psychosis) have been reported, particularly with psychoactive cannabinoids like delta-9-tetrahydrocannabinol (THC). Long-term safety data are lacking, raising concerns about the potential for adverse effects with chronic cannabinoid use, especially in vulnerable populations such as children and the elderly.

**Drug-Drug Interactions:** Cannabinoids have the potential to interact with other medications commonly used in neurological disorders, affecting drug metabolism and efficacy. Understanding the pharmacokinetic and pharmacodynamic interactions between cannabinoids and concomitant medications is essential to minimize the risk of adverse outcomes and optimize therapeutic outcomes.

**Regulatory and Legal Barriers:** Regulatory and legal barriers surrounding the use of cannabinoids pose challenges to research, patient access, and healthcare delivery. Variations in cannabis laws and scheduling of cannabinoids across different jurisdictions can hinder the conduct of clinical trials, limit patient access to cannabinoid-based therapies, and create uncertainty for healthcare providers.

**Stigma and Misconceptions:** The stigma associated with cannabis use, coupled with misconceptions about its therapeutic potential and safety, may hinder acceptance and adoption of cannabinoid-based therapies in clinical practice.

Addressing public perceptions, educating healthcare professionals, and fostering evidence-based dialogue are essential to overcome stigma and promote informed decision-making regarding cannabinoid use in neurological disorders.

**Ethical Considerations:** Ethical considerations, such as patient autonomy, informed consent, and equitable access to cannabinoid-based therapies, must be carefully considered in research and clinical practice. Ensuring that patients are fully informed about the potential risks and benefits of cannabinoid treatment and that their autonomy and privacy are respected is paramount.

In conclusion, while research into cannabinoids in neurological disorders offers exciting opportunities for therapeutic innovation, it is essential to recognize and address the limitations and drawbacks associated with this emerging field. Addressing these challenges through rigorous scientific investigation, multidisciplinary collaboration, and evidence-based policymaking is crucial to realizing the full potential of cannabinoids as therapeutic agents for neurological conditions.

## **CONCLUSION**

In conclusion, the exploration of cannabinoids as potential therapeutic agents for neurological disorders represents a dynamic and evolving field of research with significant implications for patient care, scientific understanding, and public health. While the evidence supporting the therapeutic effects of cannabinoids in neurological conditions is growing, several key conclusions can be drawn:

**Promise of Therapeutic Benefit:** Preclinical and early clinical studies suggest that cannabinoids, through their interactions with the endocannabinoid system, hold promise for alleviating symptoms and modifying disease progression in neurological disorders such as epilepsy, Parkinson's disease, Alzheimer's disease, and multiple sclerosis. Their diverse pharmacological effects, including neuroprotective, anti-inflammatory, and anticonvulsant properties, offer unique opportunities for targeting multiple disease mechanisms.

**Challenges and Limitations:** Despite the promising findings, challenges and limitations exist that must be addressed to realize the full potential of cannabinoid-based therapies. These include limited clinical evidence, heterogeneity of cannabinoid formulations, safety concerns, drug interactions, regulatory barriers, stigma, and ethical considerations. Addressing these challenges requires robust scientific research, multidisciplinary collaboration, and evidence-based policymaking.

**Need for Further Research:** There is a clear need for further research to address knowledge gaps, refine treatment strategies, and overcome existing limitations in cannabinoid research. Large-scale, well-designed clinical trials with long-term follow-up are needed to establish the safety and efficacy of cannabinoid-based therapies in different neurological disorders and patient populations. Additionally, translational studies exploring the mechanisms of action, pharmacokinetics, and pharmacodynamics of cannabinoids are essential for informing clinical practice and drug development efforts.

**Holistic Approach:** Adopting a holistic approach that considers the biopsychosocial aspects of neurological disorders is crucial. This includes addressing not only the biological mechanisms underlying disease pathology but also the psychological, social, and ethical dimensions of cannabinoid use in clinical practice. Patient-centered care, informed decision-making, and equitable access to cannabinoid-based therapies are essential considerations in this regard.

**Collaborative Efforts:** Advancing our understanding of cannabinoids in neurological disorders requires collaborative efforts across disciplines, including neuroscience, pharmacology, clinical medicine, public health, and policy. By fostering dialogue, sharing knowledge, and leveraging expertise from diverse stakeholders, we can accelerate progress towards unlocking the therapeutic potential of cannabinoids and improving outcomes for individuals living with neurological conditions.

In summary, while challenges remain, the exploration of cannabinoids in neurological disorders offers hope for novel and effective treatment approaches. By addressing existing limitations, conducting rigorous research, and fostering collaboration, we can maximize the benefits of cannabinoid-based therapies and ultimately improve the lives of patients affected by neurological disorders.

## **REFERENCES**

- [1]. Devinsky, O., Cilio, M. R., Cross, H., Fernandez-Ruiz, J., French, J., Hill, C., ... & Martinez-Orgado, J. (2014). Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. *Epilepsia*, 55(6), 791-802.
- [2]. Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., ... & Gazerro, P. (2017). Cannabidiol: State of the art and new challenges for therapeutic applications. *Pharmacology & therapeutics*, 175, 133-150.

- [3]. Fernández-Ruiz, J., Sagredo, O., Pazos, M. R., García, C., Pertwee, R., Mechoulam, R., & Martínez-Orgado, J. (2013). Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?. *British journal of clinical pharmacology*, 75(2), 323-333.
- [4]. Rosenberg, E. C., Patra, P. H., & Whalley, B. J. (2017). Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. *Epilepsy & behavior*, 70, 319-327.
- [5]. Crippa, J. A. S., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2018). Translational investigation of the therapeutic potential of cannabidiol (CBD): Toward a new age. *Frontiers in immunology*, 9, 2009.
- [6]. Hill, T. D., Cascio, M. G., Romano, B., Duncan, M., Pertwee, R. G., Williams, C. M., & Whalley, B. J. (2013). Cannabidiol-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. *British journal of pharmacology*, 170(3), 679-692.
- [7]. Morrone, L. A., Paterniti, I., Zappalà, A., & Puzzolo, D. (2018). Cannabinoids in the management of spasticity associated with multiple sclerosis. *Neuropsychiatric disease and treatment*, 14, 2579.
- [8]. Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012). Phytocannabinoids as novel therapeutic agents in CNS disorders. *Pharmacology & therapeutics*, 133(1), 79-97.
- [9]. Koppel, B. S., Brust, J. C., Fife, T., Bronstein, J., Youssof, S., Gronseth, G., & Gloss, D. (2014). Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*, 82(17), 1556-1563.
- [10]. Pisani, V., Moschella, V., Bari, M., Fezza, F., Galati, S., Bernardi, G., ... & Maccarrone, M. (2010). Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients. *Movement Disorders*, 25(7), 920-924.
- [11]. Turcotte, D., Doupe, M., Torabi, M., Gomori, A., Ethans, K., Esfahani, F., & Lau, D. (2015). Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial. *Pain Medicine*, 16(1), 149-159.
- [12]. Carroll, C. B., Bain, P. G., Teare, L., Liu, X., Joint, C., Wroath, C., ... & Wright, S. (2004). Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. *Neurology*, 63(7), 1245-1250.
- [13]. Chagas, M. H., Zuardi, A. W., Tumas, V., Pena-Pereira, M. A., Sobreira, E. T., Bergamaschi, M. M., ... & Crippa, J. A. (2014). Effects of cannabidiol in the treatment of patients with Parkinson's disease: An exploratory double-blind trial. *Journal of Psychopharmacology*, 28(11), 1088-1098.
- [14]. Colasanti, B. K., Lindamood III, C., & Craig, C. R. (1984). Effects of marijuana cannabinoids on seizure activity in cobalt-epileptic rats. *Pharmacology Biochemistry and Behavior*, 21(2), 201-208.
- [15]. Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., ... & Mechoulam, R. (1991). Controlled clinical trial of cannabidiol in Huntington's disease. *Pharmacology Biochemistry and Behavior*, 40(3), 701-708.
- [16]. Consroe, P., Sandyk, R., & Snider, S. R. (1986). Open label evaluation of cannabidiol in dystonic movement disorders. *International journal of neuroscience*, 30(4), 277-282.
- [17]. Frankel, J. P., Hughes, A., Lees, A. J., & Stern, G. M. (1990). Marijuana for parkinsonian tremor. *Journal of Neurology, Neurosurgery & Psychiatry*, 53(5), 436-436.
- [18]. Venderová, K., Růžička, E., Voříšek, V., & Visnovský, P. (2004). Survey on cannabis use in Parkinson's disease: subjective improvement of motor symptoms. *Movement Disorders*, 19(9), 1102-1106.
- [19]. Lastres-Becker, I., Molina-Holgado, F., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2005). Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. *Neurobiology of disease*, 19(1-2), 96-107.
- [20]. García, C., Palomo-Garo, C., García-Arencibia, M., Ramos, J., Pertwee, R., & Fernández-Ruiz, J. (2011). Symptom-relieving and neuroprotective effects of the phytocannabinoid  $\Delta^9$ -THCV.